Discovery and saturation analysis of cancer genes across 21 tumour types
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2-20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600-5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, the dysregulation of chromatin looping may be causally related to carcinogenesis (Extended Data Fig. 7a) 31,32.”
From The structural basis for cohesin–CTCF-anchored loops (2020) · cites this paper as [31]
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“Cancer genome sequencing has revealed that somatic mutations occur in CTCF and cohesin coding sequences in various solid tumors and leukemias (Lawrence et al., 2014), and it seems likely that these mutations contribute to oncogenesis by altering insulated neighborhoods.”
From Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control (2016) · cites this paper as Lawrence et al., 2014
In the citing paper
“The process of tumor development is strongly related to the dysfunctions caused by TP53 mutations.3,4”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
In the citing paper
“Most TP53 mutations are missense mutations located in the DBD.3,4,203,205,380”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“(5) Chromatin regulation—Five genes are associated with chromatin regulation.”
Self-citationMutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053 · cited 1×
“(4) Genome stability—Six genes encode proteins related to genome stability.”
BackgroundSelf-citationPan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870 · cited 1×
“(7) RNA processing—Three genes are associated with RNA processing and metabolism.”
BackgroundSelf-citationMapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 4×
“We ask: (1) Can large-scale genomic analysis across tumor types reliably identify all known cancer genes? (2) Will it reveal many new candidate cancer genes? (3) How far do we stand from having a complete catalog of cancer genes – at least those of intermediate frequency? We used rigorous statistical methods to enumer…”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 201–300 of 1,017
Zhang, L., Zhou, Y., Cheng, C., Cui, H., Cheng, L., Kong, P., Wang, J., Li, Y., Chen, W., Song, B., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.02.017 · Cited by 329
Pathway and network analysis of cancer genomes
the Mutation Consequences and Pathway Analysis working group of the International Cancer Genome Consortium (2015) · Nature Methods · doi:10.1038/nmeth.3440 · Cited by 325
“Recent studies have painted a portrait of the mutation landscape for multiple cancers 2 including pancreatic 3 , lung 4 , breast 5 , brain 6 , and ovarian 7 .”
Pan-cancer deconvolution of tumour composition using DNA methylation
Chakravarthy, A., Furness, A., Joshi, K., Ghorani, E., Ford, K., Ward, M. J., King, E. V., Lechner, M., Marafioti, T., Quezada, S. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05570-1 · Cited by 327
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers
Villa, G. R., Hulce, J. J., Zanca, C., Bi, J., Ikegami, S., Cahill, G. L., Gu, Y., Lum, K. M., Masui, K., Yang, H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.008 · Cited by 325
“The EGFR status of TCGA LUAD samples are designated as ‘‘EGFR Euploid’’ or ‘‘EGFR Amplification’’ based on annotations published previously (Lawrence et al., 2014). ancer Cell 30, 1–11, November 14, 2016 9”
MethodThe NCI Genomic Data Commons as an engine for precision medicine
Jensen, M. A., Ferretti, V., Grossman, R. L., & Staudt, L. M. (2017) · Blood · doi:10.1182/blood-2017-03-735654 · Cited by 324
“32 For chronic lymphocytic leukemia (CLL), this threshold is predicted to be ; 700 cases, meaning that the .”
BackgroundDNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322
“Somatic TP53 mutations are observed in around 40% of all tumours (Refs 47, 48), the mutation rate varying between cancer types from nearly 100% in ovarian cancer to 10% for haematological malignancies (Ref.”
Wang, L., Ni, X., Covington, K. R., Yang, B. Y., Shiu, J., Zhang, X., Xi, L., Meng, Q., Langridge, T., Drummond, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3444 · Cited by 323
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
Chang, Y., Park, H., Yang, H.-J., Lee, S., Lee, K.-Y., Kim, T. S., Jung, J., & Shin, J.-M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27214-6 · Cited by 320
Portrait of the PI3K/AKT pathway in colorectal cancer
Danielsen, S. A., Eide, P. W., Nesbakken, A., Guren, T., Leithe, E., & Lothe, R. A. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.008 · Cited by 321
The evolution of lung cancer and impact of subclonal selection in TRACERx
Frankell, A. M., Dietzen, M., Al Bakir, M., Lim, E. L., Karasaki, T., Ward, S., Veeriah, S., Colliver, E., Huebner, A., Bunkum, A., et al. (2023) · Nature · doi:10.1038/s41586-023-05783-5 · Cited by 313
Analysis of error profiles in deep next-generation sequencing data
Ma, X., Shao, Y., Tian, L., Flasch, D. A., Mulder, H. L., Edmonson, M. N., Liu, Y., Chen, X., Newman, S., Nakitandwe, J., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1659-6 · Cited by 318
“[14] and pediatric cancers (93”
Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance
Elhamamsy, A. R., Metge, B. J., Alsheikh, H. A., Shevde, L. A., & Samant, R. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4087 · Cited by 300
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche
Baldominos, P., Barbera-Mourelle, A., Barreiro, O., Huang, Y., Wight, A., Cho, J.-W., Zhao, X., Estivill, G., Adam, I., Sanchez, X., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.033 · Cited by 317
Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations
Li, Y. Y., Chung, G. T. Y., Lui, V. W. Y., To, K.-F., Ma, B. B. Y., Chow, C., Woo, J. K., Yip, K. Y., Seo, J., Hui, E. P., et al. (2017) · Nature Communications · doi:10.1038/ncomms14121 · Cited by 309
“3; Supplementary Data 5).”
InfluentialCRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities
Han, K., Pierce, S. E., Li, A., Spees, K., Anderson, G. R., Seoane, J. A., Lo, Y.-H., Dubreuil, M., Olivas, M., Kamber, R. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2099-x · Cited by 311
MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia
Chen, C., Liu, Y., Rappaport, A. R., Kitzing, T., Schultz, N., Zhao, Z., Shroff, A. S., Dickins, R. A., Vakoc, C. R., Bradner, J. E., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.016 · Cited by 311
“Although MLL3 is one of the most frequently mutated and deleted genes in human cancer, the biological significance of these mutations are not known (Kandoth et al., 2013; Lawrence et al., 2014).”
Extensive heterogeneity in somatic mutation and selection in the human bladder
Lawson, A. R. J., Abascal, F., Coorens, T. H. H., Hooks, Y., O’Neill, L., Latimer, C., Raine, K., Sanders, M. A., Warren, A. Y., Mahbubani, K. T. A., et al. (2020) · Science · doi:10.1126/science.aba8347 · Cited by 311
Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens
Najm, F. J., Strand, C., Donovan, K. F., Hegde, M., Sanson, K. R., Vaimberg, E. W., Sullender, M. E., Hartenian, E., Kalani, Z., Fusi, N., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4048 · Cited by 279
Recurrent and functional regulatory mutations in breast cancer
Rheinbay, E., Parasuraman, P., Grimsby, J., Tiao, G., Engreitz, J. M., Kim, J., Lawrence, M. S., Taylor-Weiner, A., Rodriguez-Cuevas, S., Rosenberg, M., et al. (2017) · Nature · doi:10.1038/nature22992 · Cited by 307
Self-citationMolecular biomarkers in acute myeloid leukemia
Prada-Arismendy, J., Arroyave, J. C., & Röthlisberger, S. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.08.005 · Cited by 304
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
“The number of genes recognized as being cancer-associated is likely to increase as new techniques are devised to identify the function of the associated proteins [162, 163].”
Papa, A., & Pandolfi, P. P. (2019) · Biomolecules · doi:10.3390/biom9040153 · Cited by 303
Histone H3 lysine 4 methyltransferase KMT2D
Froimchuk, E., Jang, Y., & Ge, K. (2017) · Gene · doi:10.1016/j.gene.2017.06.056 · Cited by 299
“What’s more striking is the frequent mutation of KMT2D in various types of cancer (Lawrence et al., 2014).”
BackgroundRubio-Perez, C., Tamborero, D., Schroeder, M. P., Antolín, A. A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., & Lopez-Bigas, N. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.007 · Cited by 296
“In the 48 cohorts under analysis (Table S1, part A), we identified 459 mutational cancer driver genes acting in one or more tumor types, supporting recent reports that many new cancer genes are yet to be identified (Lawrence et al., 2014; Vogelstein et al., 2013) (Figure 2A).”
BackgroundPatterns and functional implications of rare germline variants across 12 cancer types
Lu, C., Xie, M., Wendl, M. C., Wang, J., McLellan, M. D., Leiserson, M. D. M., Huang, K.-L., Wyczalkowski, M. A., Jayasinghe, R., Banerjee, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms10086 · Cited by 296
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Ogiwara, H., Takahashi, K., Sasaki, M., Kuroda, T., Yoshida, H., Watanabe, R., Maruyama, A., Makinoshima, H., Chiwaki, F., Sasaki, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.009 · Cited by 289
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B.-J., Wang, C., Jin, Z., Dong, B., Cao, B., Feng, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms11971 · Cited by 290
Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features
Buisson, R., Langenbucher, A., Bowen, D., Kwan, E. E., Benes, C. H., Zou, L., & Lawrence, M. S. (2019) · Science · doi:10.1126/science.aaw2872 · Cited by 318
Self-citationGanly, I., Makarov, V., Deraje, S., Dong, Y., Reznik, E., Seshan, V., Nanjangud, G., Eng, S., Bose, P., Kuo, F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.002 · Cited by 283
Horvath, L., Thienpont, B., Zhao, L., Wolf, D., & Pircher, A. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01260-z · Cited by 283
A Time to Kill: Targeting Apoptosis in Cancer
Koff, J., Ramachandiran, S., & Bernal-Mizrachi, L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16022942 · Cited by 279
Distinct Classes of Chromatin Loops Revealed by Deletion of an RNA-Binding Region in CTCF
Hansen, A. S., Hsieh, T.-H. S., Cattoglio, C., Pustova, I., Saldaña-Meyer, R., Reinberg, D., Darzacq, X., & Tjian, R. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.039 · Cited by 279
COMPASS and SWI/SNF complexes in development and disease
Cenik, B. K., & Shilatifard, A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-0278-0 · Cited by 275
Cancer-Associated PIK3CA Mutations in Overgrowth Disorders
Madsen, R. R., Vanhaesebroeck, B., & Semple, R. K. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.08.003 · Cited by 276
MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism
Bandopadhayay, P., Ramkissoon, L. A., Jain, P., Bergthold, G., Wala, J., Zeid, R., Schumacher, S. E., Urbanski, L., O'Rourke, R., Gibson, W. J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3500 · Cited by 277
The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma
McBride, M. J., Pulice, J. L., Beird, H. C., Ingram, D. R., D’Avino, A. R., Shern, J. F., Charville, G. W., Hornick, J. L., Nakayama, R. T., Garcia-Rivera, E. M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.002 · Cited by 273
“We compared the mutation frequency observed in SS patient samples with a spectrum of cancers (Cancer Genome Atlas Research Network, 2011; Lawrence et al., 2014).”
ResultRegulated Cell Death: Signaling and Mechanisms
Ashkenazi, A., & Salvesen, G. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013226 · Cited by 274
“Additional caspase-8 mutations were detected in 1–2% of colorectal cancers (Lawrence et al. 2014).”
BackgroundDawnRank: discovering personalized driver genes in cancer
Hou, J. P., & Ma, J. (2014) · Genome Medicine · doi:10.1186/preaccept-1835019729127471 · Cited by 273
“However, well-curated cancer gene databases such as CGC and the Pan-Cancer study provide an approximate benchmark of known drivers [13,42].”
BackgroundMelanocortin 1 Receptor: Structure, Function, and Regulation
Wolf Horrell, E. M., Boulanger, M. C., & D’Orazio, J. A. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00095 · Cited by 272
Clinical Implications of Genomic Discoveries in Lung Cancer
Swanton, C., & Govindan, R. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1504688 · Cited by 269
Cancer transcriptome profiling at the juncture of clinical translation
Cieślik, M., & Chinnaiyan, A. M. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.96 · Cited by 269
The AlphaFold Database of Protein Structures: A Biologist’s Guide
David, A., Islam, S., Tankhilevich, E., & Sternberg, M. J. E. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167336 · Cited by 268
Gopal, R. K., Kübler, K., Calvo, S. E., Polak, P., Livitz, D., Rosebrock, D., Sadow, P. M., Campbell, B., Donovan, S. E., Amin, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.013 · Cited by 263
Self-citationTherapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
The kinome 'at large' in cancer
Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.18 · Cited by 264
DrugComb: an integrative cancer drug combination data portal
Zagidullin, B., Aldahdooh, J., Zheng, S., Wang, W., Wang, Y., Saad, J., Malyutina, A., Jafari, M., Tanoli, Z., Pessia, A., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz337 · Cited by 263
Structural insights into the functional diversity of the CDK–cyclin family
Wood, D. J., & Endicott, J. A. (2018) · Open Biology · doi:10.1098/rsob.180112 · Cited by 260
Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis
Li, Y., Wu, X., Yang, P., Jiang, G., & Luo, Y. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.11.003 · Cited by 263
“As a result, different cancer types show different expression levels of certain proteins [84,85].”
BackgroundDoes the Immune System Naturally Protect Against Cancer?
Corthay, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00197 · Cited by 261
Schultheis, A. M., Ng, C. K. Y., De Filippo, M. R., Piscuoglio, S., Macedo, G. S., Gatius, S., Perez Mies, B., Soslow, R. A., Lim, R. S., Viale, A., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv427 · Cited by 262
Kasar, S., Kim, J., Improgo, R., Tiao, G., Polak, P., Haradhvala, N., Lawrence, M. S., Kiezun, A., Fernandes, S. M., Bahl, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9866 · Cited by 260
Self-citationHao, J.-J., Lin, D.-C., Dinh, H. Q., Mayakonda, A., Jiang, Y.-Y., Chang, C., Jiang, Y., Lu, C.-C., Shi, Z.-Z., Xu, X., et al. (2016) · Nature Genetics · doi:10.1038/ng.3683 · Cited by 259
“We first identified putative cancer driver genes based on recent large-scale ESCC sequencing data 4–8 , COSMIC cancer gene census (Aug 2015) 11 and Pan-cancer analysis 12 .”
Schulte-Sasse, R., Budach, S., Hnisz, D., & Marsico, A. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00325-y · Cited by 256
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R., Shao, W., & Sellers, W. R. (2015) · EMBO reports · doi:10.15252/embr.201439949 · Cited by 253
“However, our knowledge of important driver mutations is rapidly expanding for oncogenes mutated at lower frequency [74].”
PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis
Yu, K., Lin, C.-C. J., Hatcher, A., Lozzi, B., Kong, K., Huang-Hobbs, E., Cheng, Y.-T., Beechar, V. B., Zhu, W., Zhang, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-1952-2 · Cited by 253
Correlation of immune phenotype with IDH mutation in diffuse glioma
Berghoff, A. S., Kiesel, B., Widhalm, G., Wilhelm, D., Rajky, O., Kurscheid, S., Kresl, P., Wöhrer, A., Marosi, C., Hegi, M. E., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox054 · Cited by 254
Chiu, H.-S., Somvanshi, S., Patel, E., Chen, T.-W., Singh, V. P., Zorman, B., Patil, S. L., Pan, Y., Chatterjee, S. S., Caesar-Johnson, S. J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.064 · Cited by 254
“…Database (TAG; http://www.binfo.ncku.edu.tw/TAG/): 674 genes d Table S2 of Chen et al. (Chen et al., 2008): 766 genes d Table S2 of Lawrence et al. (Lawrence et al., 2014): 260 genes d Table S1 of Rahman et al. (Rahman, 2014): 114 genes d Network of Cancer Genes 5.0 (An et al., 2016)…”
BackgroundInfluentialSelf-citationIdentification of cancer driver genes based on nucleotide context
Dietlein, F., Weghorn, D., Taylor-Weiner, A., Richters, A., Reardon, B., Liu, D., Lander, E. S., Van Allen, E. M., & Sunyaev, S. R. (2020) · Nature Genetics · doi:10.1038/s41588-019-0572-y · Cited by 255
“Most marker papers from TCGA employ MutSigCV 10,11 or MuSiC 48 to discover cancer genes 14–16 .”
BackgroundMethodResultInfluentialSelf-citationLiquid–liquid phase separation in tumor biology
Tong, X., Tang, R., Xu, J., Wang, W., Zhao, Y., Yu, X., & Shi, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01076-x · Cited by 252
Genomic Medicine–Progress, Pitfalls, and Promise
Shendure, J., Findlay, G. M., & Snyder, M. W. (2019) · Cell · doi:10.1016/j.cell.2019.02.003 · Cited by 254
Lin, D.-C., Wang, M.-R., & Koeffler, H. P. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.06.066 · Cited by 251
Thirty years of NRF2: advances and therapeutic challenges.
Zhang, D. D. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01145-0 · Cited by 282
“Whereas NRF2 activation in normal cells suppresses tumour initiation by mitigating oxidative stress and DNA damage, its high expression in cancer cells — often driven by mutations in KEAP1, NRF2 or their regulatory proteins — confers a survival advantage 11–18 .”
Targeting Epigenetics in Cancer
Bennett, R. L., & Licht, J. D. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105106 · Cited by 246
Chang, J., Tan, W., Ling, Z., Xi, R., Shao, M., Chen, M., Luo, Y., Zhao, Y., Liu, Y., Huang, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15290 · Cited by 248
Heath, A. P., Ferretti, V., Agrawal, S., An, M., Angelakos, J. C., Arya, R., Bajari, R., Baqar, B., Barnowski, J. H. B., Burt, J., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00791-5 · Cited by 243
Genomic and immune profiling of pre-invasive lung adenocarcinoma
Chen, H., Carrot-Zhang, J., Zhao, Y., Hu, H., Freeman, S. S., Yu, S., Ha, G., Taylor, A. M., Berger, A. C., Westlake, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13460-3 · Cited by 243
Self-citationMolecular genetics of osteosarcoma
Rickel, K., Fang, F., & Tao, J. (2017) · Bone · doi:10.1016/j.bone.2016.10.017 · Cited by 244
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma
Chow, R. D., Guzman, C. D., Wang, G., Schmidt, F., Youngblood, M. W., Ye, L., Errami, Y., Dong, M. B., Martinez, M. A., Zhang, S., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4620 · Cited by 241
Keenan, T., Moy, B., Mroz, E. A., Ross, K., Niemierko, A., Rocco, J. W., Isakoff, S., Ellisen, L. W., & Bardia, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.2126 · Cited by 242
TRACERx Consortium, López, S., Lim, E. L., Horswell, S., Haase, K., Huebner, A., Dietzen, M., Mourikis, T. P., Watkins, T. B. K., Rowan, A., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0584-7 · Cited by 241
EGFR-targeted therapies in the post-genomic era
Xu, M. J., Johnson, D. E., & Grandis, J. R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9687-8 · Cited by 236
Targeting Breast Cancer Metastasis
Jin, X., & Mu, P. (2015) · Breast Cancer: Basic and Clinical Research · doi:10.4137/bcbcr.s25460 · Cited by 233
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Duffy, M. J., Synnott, N. C., & Crown, J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4753-7 · Cited by 235
Metabolic pathways in obesity-related breast cancer
Brown, K. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00487-0 · Cited by 234
Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S., Persky, N. S., Marini, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0287-5 · Cited by 230
ARID1A-mutated ovarian cancers depend on HDAC6 activity
Bitler, B. G., Wu, S., Park, P. H., Hai, Y., Aird, K. M., Wang, Y., Zhai, Y., Kossenkov, A. V., Vara-Ailor, A., Rauscher III, F. J., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3582 · Cited by 232
Sack, L. M., Davoli, T., Li, M. Z., Li, Y., Xu, Q., Naxerova, K., Wooten, E. C., Bernardi, R. J., Martin, T. D., Chen, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.037 · Cited by 229
“Analyses of point mutations can identify tumor suppressor genes (TSGs) and oncogenes (OGs) (Davoli et al., 2013; Lawrence et al., 2014; Vogelstein et al., 2013) and their distribution on chromosomes can predict the frequency of cancer somatic copy number alterations (SCNAs), indicating these are driver events (Davoli…”
Cohesin in cancer: chromosome segregation and beyond
Losada, A. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3743 · Cited by 231
Kwiatkowski, D. J., Choueiri, T. K., Fay, A. P., Rini, B. I., Thorner, A. R., de Velasco, G., Tyburczy, M. E., Hamieh, L., Albiges, L., Agarwal, N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2631 · Cited by 228
The genetic landscape of endometrial clear cell carcinomas
DeLair, D. F., Burke, K. A., Selenica, P., Lim, R. S., Scott, S. N., Middha, S., Mohanty, A. S., Cheng, D. T., Berger, M. F., Soslow, R. A., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4947 · Cited by 227
Comprehensive assessment of cancer missense mutation clustering in protein structures
Kamburov, A., Lawrence, M. S., Polak, P., Leshchiner, I., Lage, K., Golub, T. R., Lander, E. S., & Getz, G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516373112 · Cited by 225
Self-citationGenome-driven integrated classification of breast cancer validated in over 7,500 samples
Ali, H. R., Rueda, O. M., Chin, S., Curtis, C. N., Dunning, M., Aparicio, S. A. J. R., & Caldas, C. H. (2014) · Genome biology · doi:10.1186/preaccept-1094756427137059 · Cited by 225
Li, Z., Ivanov, A. A., Su, R., Gonzalez-Pecchi, V., Qi, Q., Liu, S., Webber, P., McMillan, E., Rusnak, L., Pham, C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14356 · Cited by 219
“A set of 83 genes was selected based on frequency of alterations in lung cancer and known involvement in cancer signalling pathways 19–21 .”
Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma
Lin, D.-C., Mayakonda, A., Dinh, H. Q., Huang, P., Lin, L., Liu, X., Ding, L.-W., Wang, J., Berman, B. P., Song, E.-W., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2822 · Cited by 225
Targeting EZH2 in cancer therapy
Yamagishi, M., & Uchimaru, K. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000390 · Cited by 225
Hovelson, D. H., McDaniel, A. S., Cani, A. K., Johnson, B., Rhodes, K., Williams, P. D., Bandla, S., Bien, G., Choppa, P., Hyland, F., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.03.004 · Cited by 224
Hiley, C., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014) · Genome Biology · doi:10.1186/s13059-014-0453-8 · Cited by 223
Cancer immunotherapy targeting neoantigens
Lu, Y.-C., & Robbins, P. F. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.002 · Cited by 223
Cancer Genome Evolutionary Trajectories in Metastasis
Birkbak, N. J., & McGranahan, N. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.004 · Cited by 223
Tatton-Brown, K., Loveday, C., Yost, S., Clarke, M., Ramsay, E., Zachariou, A., Elliott, A., Wylie, H., Ardissone, A., Rittinger, O., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.03.010 · Cited by 221
Michels, B. E., Mosa, M. H., Streibl, B. I., Zhan, T., Menche, C., Abou-El-Ardat, K., Darvishi, T., Członka, E., Wagner, S., Winter, J., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.04.003 · Cited by 222
Rickels, R., Herz, H.-M., Sze, C. C., Cao, K., Morgan, M. A., Collings, C. K., Gause, M., Takahashi, Y.-H., Wang, L., Rendleman, E. J., et al. (2017) · Nature Genetics · doi:10.1038/ng.3965 · Cited by 217
Buder-Bakhaya, K., & Hassel, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01474 · Cited by 217
Kampen, K. R., Sulima, S. O., Vereecke, S., & De Keersmaecker, K. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz637 · Cited by 214
Fox, D. B., Garcia, N. M. G., McKinney, B. J., Lupo, R., Noteware, L. C., Newcomb, R., Liu, J., Locasale, J. W., Hirschey, M. D., & Alvarez, J. V. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0191-z · Cited by 210
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
Braun, D. A., Moranzoni, G., Chea, V., McGregor, B. A., Blass, E., Tu, C. R., Vanasse, A. P., Forman, C., Forman, J., Afeyan, A. B., et al. (2025) · Nature · doi:10.1038/s41586-024-08507-5 · Cited by 207
Self-citationBladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting
Lerner, S. P., McConkey, D. J., Hoadley, K. A., Chan, K. S., Kim, W. Y., Radvanyi, F., Höglund, M., & Real, F. X. (2016) · Bladder Cancer · doi:10.3233/blc-150037 · Cited by 213
Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study
Shi, J., Hua, X., Zhu, B., Ravichandran, S., Wang, M., Nguyen, C., Brodie, S. A., Palleschi, A., Alloisio, M., Pariscenti, G., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002162 · Cited by 212
Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology
Becker, A., Sells, B., Haque, S., & Chakravarti, A. (2021) · Cancers · doi:10.3390/cancers13040761 · Cited by 212
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Venue
- Nature
- Published
- 2014-01
- Volume
- 505
- Issue
- 7484
- Pages
- 495-501
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4048962
- OpenAlex
- W2114031931
- Cited by
- 3,096
- References
- 13
- Citations by year
- 2026: 103 · 2025: 188 · 2024: 202 · 2023: 223 · 2022: 235 · 2021: 241 · 2020: 277 · 2019: 268 · 2018: 264 · 2017: 312 · 2016: 305 · 2015: 291 · 2014: 177
- FWCI
- 116.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R01CA157304)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- cancer genes, somatic point mutations, cancer types, saturation analysis, mutation frequency, exome sequencing, sample size determination, mutation rate heterogeneity, cancer genomics
- MeSH terms
- Chromatin, DNA Mutational Analysis, Humans, Neoplasms, RNA Processing, Post-Transcriptional, Genome, Human, Case-Control Studies, Apoptosis, Point Mutation, Sample Size, Genomics, Genomic Instability, Cell Proliferation, Genes, Neoplasm, Immune Evasion, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.